Liver-Directed Therapies for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma

• Published in: Cancer Control Vol. 24; no. 3; p. 1073274817729244
• Main Authors: Kis, Bela, El-Haddad, Ghassan, Sheth, Rahul A., Parikh, Nainesh S., Ganguli, Suvranu, Shyn, Paul B., Choi, Junsung, Brown, Karen T.
• Format: Book Review Journal Article
• Language: English
• Published: Los Angeles, CA SAGE Publications 01.07.2017; H. Lee Moffitt Cancer Center and Research Institute; Sage Publications Ltd
• Subjects: Ablation (Surgery); Biliary tract cancer; Carcinoma, Hepatocellular - pathology; Carcinoma, Hepatocellular - therapy; Care and treatment; Chemoembolization, Therapeutic - methods; Cholangiocarcinoma; Clinical trials; Hepatocellular carcinoma; Humans; Liver cancer; Liver Neoplasms - pathology; Liver Neoplasms - therapy; Medical treatment; Patients; Review; Risk factors; percutaneous ablation; radioembolization; chemoembolization; cholangiocarcinoma; hepatocellular carcinoma
• ISSN: 1073-2748; 1526-2359; 1073-2748
• DOI: 10.1177/1073274817729244

Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (IHC) are primary liver cancers where all or most of the tumor burden is usually confined to the liver. Therefore, locoregional liver-directed therapies can provide an opportunity to control intrahepatic disease with minimal systemic side effects. The English medical literature and clinical trials were reviewed to provide a synopsis on the available liver-directed percutaneous therapies for HCC and IHC. Locoregional liver-directed therapies provide survival benefit for patients with HCC and IHC compared to best medical treatment and have lower comorbid risks compared to surgical resection. These treatment options should be considered, especially in patients with unresectable disease.